MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/07853890.2025.2573150

Медицинская библиотека · Annals of medicine · 2025

Prognostic value of preablative stimulated thyroglobulin and its decline after 131I therapy in differentiated thyroid cancer.

Wang Jingjing, Hou Yuyue, Tan Jie, Zhang Yajing, Wu Ruolin, Han Yanmei, Ren Xiaojing, Xia Xiaotian, Gao Zairong

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

The incidence of differentiated thyroid cancer (DTC) has been increasing, highlighting the need for reliable predictors of treatment response. This study aimed to assess the prognostic value of stimulated thyroglobulin (sTg) levels before and after the first 131I treatment in DTC patients without distant metastases.

METHODS

Sixty patients were classified into excellent response (ER) and non-excellent response (NER) groups based on a comprehensive evaluation of imaging findings, sTg, suppressed Tg and other parameters. Clinical and pathological variables were analyzed using univariate and multivariate logistic regression. Receiver operating characteristic (ROC) curve analysis was used to determine optimal cut-off values for pre-131I sTg levels and for the rate of sTg decline after the first 131I therapy.

RESULTS

Both pre-131I sTg level (OR: 3.010, 95% CI: 1.004-9.029, p = 0.049) and the rate of sTg decline (OR: 0.756, 95% CI: 0.590-0.968, p = 0.026) were identified as independent predictors of clinical outcomes. The optimal threshold for pre-131I sTg was 14.55 μg/L (sensitivity: 95.0%, specificity: 67.5%, AUC: 0.804), and for the rate of sTg decline, 44.75% (sensitivity: 70.0%, specificity: 97.5%, AUC: 0.889). A prognostic nomogram was developed incorporating sex, age, pre- and post-131I sTg levels, T and N stages, tumor size, and thyroiditis.

CONCLUSION

Lower pre-131I sTg levels and/or a greater rate of sTg decline after the first 131I treatment are associated with more favorable clinical outcomes. The proposed nomogram may assist clinicians in optimizing treatment decisions and stratifying follow-up strategies for patients with DTC.

Для цитирования: Wang Jingjing, Hou Yuyue, Tan Jie, Zhang Yajing, Wu Ruolin, Han Yanmei, Ren Xiaojing, Xia Xiaotian, Gao Zairong. Prognostic value of preablative stimulated thyroglobulin and its decline after 131I therapy in differentiated thyroid cancer.. Annals of medicine. 2025. DOI: 10.1080/07853890.2025.2573150.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.